Daniel Griffith Anderson

Insider Reports History

Entity
Individual
Location
C/O Sigilon Therapeutics, Inc., 100 Binney Street, Suite 600, Cambridge, MA
Signature
/s/ Matthew Kowalsky, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Daniel Griffith Anderson:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Sigilon Therapeutics, Inc. Director Common Stock 2.02M $30.2M $14.92 Jun 2, 2021 Direct

Insider Reports Filed by Daniel Griffith Anderson

Symbol Company Period Transactions Value $ Form Type Date Filed Role
SGTX Sigilon Therapeutics, Inc. Jun 2, 2021 1 -$2M 4 Jun 4, 2021 Director